



(86) Date de dépôt PCT/PCT Filing Date: 2004/11/26
 (87) Date publication PCT/PCT Publication Date: 2005/06/09
 (85) Entrée phase nationale/National Entry: 2006/05/24
 (86) N° demande PCT/PCT Application No.: EP 2004/013450
 (87) N° publication PCT/PCT Publication No.: 2005/051999
 (30) Priorité/Priority: 2003/11/26 (EP03 027 000.3)

(51) Cl.Int./Int.Cl. *C07K 14/705* (2006.01),
A61K 39/00 (2006.01), *A61K 38/17* (2006.01),
C07K 16/28 (2006.01), *C12N 15/12* (2006.01),
C12N 15/63 (2006.01), *G01N 33/53* (2006.01),
G01N 33/68 (2006.01)

(71) Demandeur/Applicant:
 MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG
 DER WISSENSCHAFTEN E.V., DE

(72) Inventeurs/Inventors:
 HUBER, ROBERT, DE;
 SONDERMANN, PETER, DE;
 JACOB, UWE, DE;
 WENDT, KERSTIN, AT;

...

(54) Titre : SUBSTANCE SE LIANT AU RECEPTEUR HUMAIN IIB POUR LE FC DES IGG
 (54) Title: SUBSTANCE BINDING HUMAN IGG FC RECEPTOR IIB

(57) **Abrégé/Abstract:**

The invention relates to novel immunogens carrying conformationally discriminating epitopes (CDEs) and to immunization methods for producing antibodies that specifically recognize proteins with very closely related homologues. In particular, the invention relates to antibodies which are specific for either FcγRIIb or FcγRIIa.

(72) Inventeurs(suite)/Inventors(continued): CHIARA, CABRELE, DE; MORODER, LUIS, DE

(74) Agent: OGILVY RENAULT LLP/S.E.N.C.R.L., S.R.L.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
9 June 2005 (09.06.2005)

PCT

(10) International Publication Number
WO 2005/051999 A3

- (51) International Patent Classification⁷: **C07K 14/705**, 16/28, C12N 15/12, 15/63, A61K 38/17, 39/00, G01N 33/53, 33/68
- (21) International Application Number: PCT/EP2004/013450
- (22) International Filing Date: 26 November 2004 (26.11.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 03 027 000.3 26 November 2003 (26.11.2003) EP
- (71) Applicant (for all designated States except US): **MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.** [DE/DE]; Hofgartenstrasse 8, 80539 München (DE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **HUBER, Robert** [DE/DE]; Schlesier Str. 13, 82110 Germering (DE). **SONDERMANN, Peter** [DE/DE]; Margaretenstrasse 54a, 82152 Krailling (DE). **JACOB, Uwe** [DE/DE]; Guldeinstrasse 42, 80339 München (DE). **WENDT, Kerstin** [DE/AT]; Enekelstr. 8/30, A-1160 Wien (AT). **CHIARA, Cabrele** [IT/DE]; Schwabelweiserweg 22, 93059 Regensburg (DE). **MORODER, Luis** [IT/DE]; Alexander-Fleming-Strasse 10d, 82152 Martinsried (DE).
- (74) Agents: **WEICKMANN & WEICKMANN** et al.; Postfach 860 820, 81635 München (DE).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- (88) Date of publication of the international search report: 24 November 2005
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SUBSTANCE BINDING HUMAN IGG FC RECEPTOR IIB

(57) Abstract: The invention relates to novel immunogens carrying conformationally discriminating epitopes (CDEs) and to immunization methods for producing antibodies that specifically recognize proteins with very closely related homologues. In particular, the invention relates to antibodies which are specific for either FcγR11b or FcγR11a.



WO 2005/051999 A3

DEMANDES OU BREVETS VOLUMINEUX

**LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.**

CECI EST LE TOME __1__ DE __2__

NOTE: Pour les tomes additionels, veuillez contacter le Bureau Canadien des Brevets.

JUMBO APPLICATIONS / PATENTS

**THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.**

THIS IS VOLUME __1__ OF __2__

NOTE: For additional volumes please contact the Canadian Patent Office.

Substance binding human IgG Fc receptor IIb (FcγRIIb)

Description

The invention relates to novel immunogens carrying conformationally discriminating epitopes (CDEs) and to immunization methods for producing
5 antibodies that specifically recognize proteins with very closely related homologues. In particular, the invention relates to antibodies which are specific for either FcγRIIb or FcγRIIa and which are useful for the diagnosis and treatment of autoimmune diseases, infections, tumors and other conditions where the immune system is involved.

10

Fc receptors (FcRs) play a key role in defending the human organism against infections. After pathogens have gained access to the blood circulation they are opsonized by antibodies (immunoglobulins, Igs). This leads to the formation of immune complexes. The Fc portions of the
15 antibodies can bind to Fc receptors which are present on virtually all cells of the immune system. Specific FcRs exist for all Ig classes. The Greek letter indicates the Ig class to which it binds, i.e. Fcγ receptors recognize IgG etc.

20

It has been known for a number of years that the Fc receptors for IgG (FcγR) play an important role in triggering effector responses (Metzger, 1992A). These include, depending on the expressed FcγR and cell type, endo- and phagocytosis resulting in neutralization of the pathogens and antigen presentation, antibody-dependent cell-mediated cytotoxicity (ADCC), neutrophil activation, regulation of the antibody production or the secretion
25 of inflammatory mediators (Fridman et al., 1992; van de Winkel and Capel, 1993; Ravetch and Bolland, 2001).

30

In contrast to the beneficial role FcRs play in the healthy individual, they also transmit the stimulation of the immune system in allergies (e.g. mediated by FcεRIa) or autoimmune diseases. Moreover, some viruses

- 2 -

employ Fc γ Rs to get access to cells like HIV (Homsy et al., 1989) and Dengue (Littaua et al., 1990) or slow down the immune response by blocking Fc γ Rs as in the case of Ebola (Yang et al., 1998) and Measles (Ravanel et al., 1997).

5

Fc receptors for IgG (Fc γ R) are the most widespread of the Fc receptor family and are expressed in a defined pattern on all immunological active cells. Fc γ RI is constitutively expressed on monocytes and macrophages and can be induced on neutrophils and eosinophils. The physiological role of Fc γ RI is still unknown as the expression on monocytes is not vital (Ceuppens et al., 1988). The glycosylphosphatidylinositol-anchored form (GPI) of Fc γ RIII (Fc γ RIIIb) is exclusively expressed on granulocytes. Due to its missing cytoplasmic part, the signal transduction into the cell occurs solely via other transmembrane proteins like complement receptor type 3 (CR3) that can at least associate with Fc γ RIIIb (Zhou et al., 1993; Poo et al., 1995). Fc γ RIIIa is mainly expressed on monocytes and macrophages but only in conjunction with an associated protein called γ -chain. Fc γ RIIIa is the receptor with the widest distribution on immune competent cells and is mainly involved in the endocytosis of immune complexes. Fc γ RIIb is expressed on B cells where it is the only IgG receptor, and on effector cells such as macrophages, neutrophils and mast cells, but not on NK cells and T cells.

10
15
20

Structurally, the extracellular part of the Fc γ Rs consists of three (Fc γ RI, CD64) or two (Fc ϵ RI, Fc γ RII, CD32 and Fc γ RIII, CD16) Ig-like domains (ca. 10 kDa/domain) and therefore belong to the immunoglobulin super family. In addition to the extracellular domains, FcRs have a transmembrane domain, and an intracellular domain with the exception of the GPI-anchored Fc γ RIIIb. The receptors are homologous to each other, and the overall identity in amino acid sequence among the Fc γ Rs and the Fc ϵ RIa exceeds 40% in their extracellular regions. Fc γ RIIIa and Fc γ RIIb differ in their extracellular region

25
30

- 3 -

by only 6% of the amino acid residues. Nevertheless, both forms can be distinguished by their binding characteristics to human and mouse IgG subclasses (van de Winkel and Capel, 1993) and their differing affinity to human IgGs (Sondermann et al., 1999A).

5

FcRs are highly glycosylated. The cDNA sequence of many Fc receptors is known, and some soluble recombinant FcR have been generated. Soluble recombinant Fc receptors which are characterised by an absence of transmembrane domains, signal peptide and glycosylation are disclosed in WO 00/32767.

10

FcγRs occur in various isoforms (FcγRIa, b1, b2, c; FcγRIIa1-2, b1-3, c) and alleles (FcγRIIa1-HR, -LR; FcγRIIb-NA1, -NA2) (van de Winkel and Capel, 1993). In contrast to the overall homologous extracellular parts, the membrane spanning and the cytoplasmic domains of up to 8 kDa large differ.

15

The FcγRs can be divided into two general classes according to their function which may be an activating or an inhibitory one. The activating receptors are associated with a cytoplasmic 16 amino acid immunoreceptor tyrosine-based activation motif (ITAM) having the consensus sequence Y-X₂-L/I-X₈-Y-X₂-L/I (Isakov, 1997). This motif can be found, for example in FcγRIIa. The other class of FcRs are inhibitory receptors which have a cytoplasmic 6 amino acid inhibitory motif (ITIM) having the consensus sequence V/I-X-Y-X₂-V/L (Isakov, 1997). An example of such an inhibitory FcR is FcγRIIb.

20
25

Activation and inhibition via the ITAM and ITIM motifs is effected by tyrosine phosphorylation. Depending on the particular cell type, activated by the Fc receptor, different tyrosine kinases are involved in these signaling pathways (Amigorena et al., 1992). Both activating and inhibiting FcγRs may be expressed on the same cell which allows functioning of activation and inhibitory receptors in concert for a fine tuning of the immune response.

30

Fc γ RIIb has two inhibitory activities. One of these is dependent on the ITIM motif and occurs when Fc γ RIIb is ligated to an ITAM-carrying receptor (e.g. Fc γ RIIa) resulting in the inhibition of ITAM-triggered calcium mobilization and cellular proliferation. This means that calcium-dependent processes such as degranulation, phagocytosis, ADCC, cytokine release and pro-inflammatory activation, and also B cell proliferation are blocked by Fc γ RIIb. The second inhibitory activity of Fc γ RIIb involves homo-aggregation of the receptor (Fc γ RIIb clustering) which delivers a pro-apoptotic signal into the cytoplasm. The pro-apoptotic signal has only been reported in B cells and can be blocked by ligation of Fc γ RIIb to the B cell receptor (BCR). In vivo studies suggest that Fc γ RIIb plays a role in peripheral tolerance because Fc γ RIIb-knockout mice develop spontaneously autoimmune diseases. On the other hand, Fc γ RIIb has also been reported to down-regulate cytotoxicity against tumors (Clynes et al., 2000). Mice deficient in Fc γ RIIb and treated with an anti-tumor antibody showed enhanced ADCC resulting in a reduction of tumor metastasis, whereas mice deficient in activating Fc receptors were unable to arrest tumor growth, when treated with the same antibody.

The generation of antibodies by immunising animals with proteins or peptides as immunogens is known in the art. Conventional immunisation protocols use linear peptides as immunogens which are derived from antigens of interest. The disadvantage of such methods is that because the three-dimensional structure of the epitopes is often completely lost, the resulting antibodies are not very specific or they comprise a large fraction of antibodies directed to epitopes other than the one of interest.

During the last decade, immunization protocols using Fc-receptor expressing cells or denatured Fc-receptors have only resulted in antibodies that were able to specifically detect denatured Fc-Receptors (Western Blot) or were not able to discriminate between the related Fc γ RIIa and Fc γ RIIb on cell

- 5 -

lines (e.g. U-937, Raji) or blood cells. To date, there are no antibodies or other binding substances which bind selectively and specifically to Fc γ RIIb in its native conformation and/or its natural environment.

5 Conventional immunization protocols involving peptides or recombinant proteins as antigens are not well suited to produce specific antibodies against proteins for which homologues with very high sequence identity exist. In general, antibodies are raised using small linear peptides as immunogens. Such peptides do not represent the native conformation of the
10 epitope on the protein from which they are derived. In addition, the large majority of the antibodies produced by the immunized animal are directed against epitopes of the carrier protein to which the antigen is conjugated or against epitopes on the recombinant antigen that are common to the homologues. In consequence, the produced antibodies are not specific
15 and/or fail to detect the antigen in its native conformation. Furthermore, glycosylation sites might be located within the epitopes of interest and mask these sites. Conventional immunization protocols which use these epitopes without the respective native glycosylation found in the target molecule result in antibodies that fail to recognize the antigen in its native
20 conformation.

One object of the present invention is to provide recombinant peptides or polypeptides which can be used as immunogens to raise antibodies capable of discriminating between an antigen of interest and closely related antigens,
25 and a method of generating such peptides and the corresponding antibodies and other substances having immunological specificity.

It is a further object of the present invention to provide substances which can selectively bind to and discriminate between Fc receptor subtypes, thereby
30 acting as an Fc receptor binding substance useful for the treatment and diagnosis of immune disorders, in particular autoimmune diseases, and as anti-tumor agents which enhance the efficiency of such therapies by promoting ADCC against tumor cells.

- 6 -

It is a further object of the present invention to provide an immunization protocol that will allow the generation of such FcγRIIb-binding substances, in particular antibodies, especially monoclonal antibodies with the above-mentioned specificity.

The inventors of the present invention have found a novel and inventive approach to developing substances, in particular antibodies, that are capable of discriminating between very closely related proteins and/or proteins and antigens with high homology.

Surprisingly, it was found that it is possible to raise specific antibodies against proteins of interest when so-called conformationally discriminating epitopes (CDEs) are used as the antigen to which the antibodies are raised.

The present invention therefore relates to an artificial peptide or polypeptide comprising a conformationally discriminating epitope (CDE) in its native conformation, wherein the CDE is structurally stabilized by circularization.

For the purposes of the present invention, an artificial peptide or polypeptide is one that is produced by any technical process such as recombinant techniques or preferably by peptide synthesis.

A CDE is an epitope in a protein which has a specific conformation in the protein. Antibodies which are specific for such an epitope can discriminate between a protein and very closely related homologues. The CDE comprises at least one amino acid which differs between the protein in which it is present and the homologues of that protein (unique residue). The unique residues need not be in close proximity in the linear sequence of the protein in order to be part of the same epitope. The advantage of the present invention is that the peptides of the invention do not just have the linear sequence of those epitopes but mimic also their structure. The CDE contains at least one of such unique residues, preferably at least two, more

- 7 -

preferably more than two of such unique residues. The CDE represents the binding site for an antibody.

5 The peptides of the present invention preferably have a length of from 5, more preferably from about 8, more preferably from about 10 to about 30, more preferably to about 20, more preferably to about 18, more preferably to about 15 amino acids.

10 Structural stabilization in this context means that the peptide is stabilized so that the CDE is present in as close to its native three-dimensional conformation in the original protein as possible. Structural stabilization can be achieved by a number of means. In particular, the peptide is circularized so that it forms a stable three-dimensional structure such as a loop. Stabilizing the peptide can be achieved by N- to C-terminal coupling, the
15 formation of cysteine bridges or by bridging amino acid side chains. Pseudopeptides can be formed.

20 Preferably, the peptide or polypeptide of the present invention also carries glycosylation moieties. The peptide is preferably generated so that glycosylated amino acids are incorporated at the same sites which are glycosylated in the native protein from which the CDE is derived. Preferably, the glycosylated amino acids are selected from N-acetyl-glucosamine, fucose, xylose, mannose, and galactose conjugates but this list is not exhaustive. If the discriminating epitope contains a N-glycosylation site, an
25 artificial conjugate of an asparagine residue with a N-acetyl-glucosamine may be incorporated into the peptide, to enhance the probability that the natively glycosylated substrate is recognized by the resulting antibodies after successful immunization. Accordingly for O-glycosylation sites, a serine or threonine residue may be conjugated with a mannose, fucose, xylose,
30 galactose or N-Acetyl-galactosamine residue respectively.

The peptides and polypeptides of the invention may additionally be coupled to a carrier molecule. Such carrier molecules are preferably selected from

- 8 -

haptens, peptides, polypeptides and other immunogens. The peptides of the invention may be grafted onto other peptides and proteins, even the same protein or parts thereof from which the CDE was derived.

5 A preferred embodiment of the invention is a peptide carrying a CDE from an Fc receptor. The inventors of the present invention surprisingly found that there are specific epitopes on the extracellular portion of FcγRIIb which allow the generation of antibodies which bind specifically to FcγRIIb. This is particularly useful because the family of Fc receptors comprises unusually
10 closely related homologues which are difficult to distinguish using conventional antibodies. In particular, the present invention makes it possible to generate substances which bind to FcγRIIb but not to FcγRIIa and vice versa. Similarly, the epitopes can be chosen so that FcγRIIa is specifically recognized.

15 In particular, the peptides or polypeptides according to the present invention comprise an epitope comprising at least one, preferably at least 2, preferably at least 3 of the following amino acids of the amino acid sequence of human FcγRIIb according to Figure 1 and SEQ ID NO: 2: Gln12, Arg27, Thr29,
20 His30, Val104, Lys127, Ser132, Asn135, Tyr160, and Ala171, or the corresponding amino acids of FcγRIIa according to SEQ ID NO: 1. More preferably, the epitopes useful for the purposes of the present invention comprise amino acids 27 to 30, and/or 127 to 135, and/or 160 to 171 of the amino acid sequence of FcγRIIb (Figure 1, SEQ. ID NO: 2), or the
25 corresponding amino acids of FcγRIIa (Figure 1). These peptides can represent FcγRIIb-specific conformationally discriminating epitopes (CDEs), when structurally stabilized by circularization, in an adequate way as exemplified in Figure 2. Also, the corresponding epitopes of FcγRIIa may be used to produce antibodies that specifically bind only to FcγRIIa.

30

- 9 -

Especially peptides comprising the amino acid sequence 127-KKFSRSDPN-135 and flanking amino acids are preferred because these peptides represent a FcγRIIb-specific conformational epitope within the binding region of the Fc-Receptor to the Fc-fragment (WO 00/32767, Sondermann et al., 2000; Sondermann et al., 2001). Furthermore peptides containing the amino acid sequence 28-RGTH-31 and flanking residues are preferred because they represent a binding epitope apart from the binding region to the Fc-fragment. Moreover, this epitope may be further adapted to the native structure by circularisation and incorporation of a glycosylated asparagine residue at position 135.

Thus, a preferred embodiment of the present invention is a peptide or polypeptide carrying the CDE according SEQ ID NO: 3. Preferably, the asparagine of position 135 (according to SEQ ID NO: 2) is glycosylated with N-acetyl-glucosamine. Preferably, the peptide is as shown in Figure 7, being circularized by linking the first and last amino acids in the sequence as shown in Figure 7.

These artificial peptides can then be used directly for the immunization of animals or may be coupled to a carrier protein such as haptens or peptides or polypeptides, or ideally to the target protein itself. In a preferred embodiment, a CDE from FcγRIIb or FcγRIIa or a peptide carrying such a CDE is conjugated to FcγRIIb or FcγRIIa.

The peptides and polypeptides of the present invention are preferably used as immunogens to immunize animals in order to generate specific antibodies and, with the aid of the sequence of those specific antibodies, further immunologically specific substances. The CDEs and the peptides carrying them may be used for the generation of immunomodulatory substances specifically recognizing the CDE. This is particularly preferred when CDEs of Fc receptors are chosen because they allow the generation of antibodies specific for individual members of the family of homologues. In particular, antibodies and other immunomodulatory substance recognizing either

- 10 -

Fc γ R1Ib or Fc γ R1Ia but not both at the same time, can be generated. The present invention allows the generation of antibodies which are capable not only of specifically recognizing Fc γ R1Ib or Fc γ R1Ia and discriminating between the two Fc receptors but also of doing so when the Fc receptors are in their natural environment, for example in cell culture or in vivo, e.g. in the blood stream.

By coupling of the CDE to the protein from which it was derived, the background immune reaction against the carrier protein is reduced. The artificial modification by the covalently coupled CDE results in an increased immune response. This is especially important if the immunized animal expresses similar proteins which would be tolerated by its immune system. Thus, if the peptide of the invention carries a CDE of Fc γ R1Ib or Fc γ R1Ia, it is preferably coupled to the respective Fc receptor itself. This increases the antigenicity. The coupling can occur by chemical linkage or other suitable means.

This method preferably produces an immunogen with a high density of CDEs thereby presenting them in a different thus immunogenic environment. The initial immune response is directed against the targeted region (CDE) which produces antibodies that crossreact with the native structure to which they are coupled. These crossreacting antibodies mature towards higher affinity also recognizing the CDE in its natural environment.

The peptides of the invention and the CDEs may also be used in screening of molecular libraries for binding molecules (e.g. peptides, organic molecules, peptidomimetics etc.) or genetically encoded libraries (e.g. phage display of antibody variable domains or other frameworks like lipocalins) to find specifically binding substances to Fc γ R1Ib (or to Fc γ R1Ia). The peptides may be used to screen libraries of molecules binding specifically to either Fc γ R1Ia or Fc γ R1Ib on human cells.

- 11 -

Similar peptides according to the invention can be extracted from the structure of other proteins, e.g. receptors, that are related to each other but which have different functions (e.g. human FcγRIIIa-specific antibodies can be developed that do not recognize FcγRIIb, which may be incorporated in
5 Diabodies or Triabodies, to promote ADCC which is mediated by FcγRIIIa rather than by FcγRIIIb) or which occur in different alleles (e.g. FcγRIIIa Arg/His-polymorphism at position 131, or FcγRIIIa Phe/Val-polymorphism at position 155).

10 Another use of the novel peptides of the invention is a direct use as inhibitors of promoters of immunological functions. The peptides according to the invention may be used directly for immunotherapies.

The above-described peptides of the invention can be produced by a novel
15 method, wherein the method comprises:

- (a) providing a protein of interest,
- (b) identifying a CDE on that protein,
- (c) producing a peptide comprising the sequence of the CDE,
- (d) structurally stabilizing the peptide so that the CDE is present in
20 its native conformation.

The peptide is structurally stabilized by circularisation, preferably by N- to C-terminal coupling, the formation of cysteine bridges, and/or bridging amino acid side chains forming a pseudopeptide. As stated above, the peptide is
25 preferably generated using amino acids carrying glycosylation moieties which are present on the protein of interest. The method preferably comprises the additional step of conjugating the peptide to a carrier molecule which can be selected from any of the molecules mentioned above. Another aspect of the present invention is a peptide or polypeptide
30 comprising a CDE, obtainable by the method of the invention.

- 12 -

In order to significantly raise the fraction of specifically binding antibodies, the invention provides the following method for generating specific binding substances capable of discriminating between an antigen of interest and closely related antigens, wherein the method comprises immunising an animal with a peptide or polypeptide according to the present invention or/and with a correctly folded portion of the antigen of interest, in particular a peptide derived from an Fc receptor such as FcγRIIb or FcγRIIa, and isolating the resulting antibodies, and optionally using the antibodies to generate recombinant immunomodulatory substances.

To produce antibodies that discriminate between an antigen A and an antigen B with high sequence identity to A, the differing amino acids are mapped to the structure of A or a respective structure model of A. Differing amino acids that are separated by several amino acids in the primary sequence may be in spatial proximity. In case that these differing amino acids are accessible from the solvent in the native structure these surface regions can be regarded as conformationally discriminating epitopes (CDE). Such epitopes can be artificially constructed by cyclic peptides or peptide analogues and are especially useful for the generation of antibodies that can discriminate between strongly related antigens.

In a variation of this method transgenic animals are used for immunization that are engineered to express the close homologue(s) and are later immunized with the target antigen. Animals that express the human FcγRIIb are immunized with human FcγRIIa or vice versa.

In a particularly preferred aspect, the present invention provides an FcγRIIb-binding antibody or fragment or derivative thereof, capable of specifically binding to FcγRIIb or to FcγRIIa in the natural environment of the Fc receptor. Such antibodies fragments or derivatives can discriminate between the closely related homologues of FcγRIIb and FcγRIIa in a natural environment, e.g in cell culture or in vivo.

- 13 -

In a preferred embodiment, the Fc γ RIIb- (or Fc γ RIIa-) binding antibody or fragment or derivative thereof not only binds specifically to Fc γ RIIb (or Fc γ RIIa) but also prevents the natural binding partners of Fc γ RIIb (or Fc γ RIIa), i.e. IgG antibodies, from binding.

In another preferred embodiment of the present invention, the specific anti-Fc γ RIIb (or anti- Fc γ RIIa) antibodies are non-blocking and recognize an epitope distinct from the Fc-receptor/Fc-fragment interaction site(e.g. an epitope of the N-terminal domain around the amino acids 28-31). In contrast to blocking antibodies these antibodies have the advantage that binding of the receptor to immune complexes is not impaired. The result is that the activation of the receptors by immune complexes remains intact and additional receptors can be recruited to enhance the activation.

It is thus possible to modulate the natural functions of these Fc receptors independent of IgG binding. For example, the antibody or fragment or derivative thereof may be chosen to be capable of crosslinking the Fc receptor. That way, the receptor can be activated. Preferably, the antibody or fragment or derivative thereof of the invention does not interfere with immune complex binding to Fc γ RIIb or Fc γ RIIa.

On the other hand, the antibody or fragment or derivative thereof may be chosen so that it inhibits the physiological function of human Fc γ RIIa or Fc γ RIIb.

The antibody or derivative or fragment of the invention preferably binds with higher affinity to Fc γ RIIb than to Fc γ RIIa. The antibody or fragment or derivative thereof binds Fc γ RIIb with at least 5 fold, preferably at least 10 fold, preferably at least 100fold, more preferably at least 1,000fold, more preferably at least 10,000fold, more preferably at least 100,000fold, more

- 14 -

preferably at least 10^6 fold, more preferably at least 10^7 fold, more preferably at least 10^8 fold, more preferably at least 10^9 fold, more preferably 10^{10} fold, more preferably 10^{11} fold, more preferably 10^{12} fold higher affinity than Fc γ R11a. Alternatively, the antibody or fragment or derivative binds Fc γ R11a with at least 5fold, preferably at least 10fold, preferably at least 100fold, more preferably at least 1,000fold, more preferably at least 10,000fold, more preferably at least 100,000fold, more preferably at least 10^6 fold, more preferably at least 10^7 fold, more preferably at least 10^8 fold, more preferably at least 10^9 fold, more preferably 10^{10} fold, more preferably 10^{11} fold, more preferably 10^{12} fold higher affinity than Fc γ R11b. 5, 10, 100, 1000 or even more than 1,000,000 fold tighter binding to the specific Fc-receptor is necessary to overcome the much higher expression level of Fc γ R11a on platelets over Fc γ R11b.

The antibody or fragment or derivative thereof can occur in a monomeric or multimeric state.

The antibody or fragment or derivative thereof may be capable of binding Fc receptor molecules with or without cross-linking them on the cell surface. Preferably, the antibody or fragment or derivative thereof is multimeric in order to cross-link Fc γ R11a or Fc γ R11b. Alternatively, the antibody or fragment or derivative thereof is monomeric and able to block IgG binding to human Fc γ R11b, but preferably not able to cross-link Fc γ R11b.

The antibody or fragment or derivative thereof of the invention may also be modified in the Fc-fragment by the modification of the glycosylation and/or mutagenesis to enhance the binding towards subsets of the Fc-receptors.

The antibody or fragment or derivative thereof of the invention is preferably able to bind to a CDE or/and peptide as described above, in particular those comprising one or more of the amino acids of human Fc γ R11b according to Figure 1 and SEQ ID NO: 2, selected from: Gln12, Arg27, Thr29, His30,

- 15 -

Val104, Lys127, Ser132, Asn135, Tyr160, and Ala171, or the corresponding amino acids of FcγRIIIa according to SEQ ID NO: 1. More preferably, the substance binds to an epitope comprising amino acids 27 to 30, and/or 127 to 135, and/or 160 to 171 of the amino acid sequence of FcγRIIb (Figure 1, SEQ ID NO: 2) or the corresponding epitopes of FcγRIIIa.

In a similar way human FcγRIIIa-specific antibodies can be developed that do not recognize FcγRIIIb, which may be incorporated in Diabodies or Triabodies, to promote ADCC which is mediated by FcγRIIIa rather than by FcγRIIIb.

The antibody or fragment or derivative thereof can be any natural, artificial or recombinantly produced substance carrying a region which can bind to the above-mentioned epitopes of FcγRIIb. Preferably, this region contains the complementarity determining regions (CDRs) of the antibody which bind specifically to FcγRIIb. More preferably, the CDRs comprise the sequences as depicted in Figures 5 and 6.

The described CDRs maybe the basis for variations to further improve their specificity or designing new specific or pan-antibodies (or binding molecules) for other selected Fc-Receptors or receptor groups. Methods are known that include random or site directed mutagenesis, screening for related sequences and knowledge- or structure-based design.

Preferably, the antibody or fragment or derivative thereof comprises one or both of the variable light and variable heavy regions according to SEQ ID Nos: 5 and 7, and/or the variable light and variable heavy regions according to SEQ ID Nos: 9 and 11. Most preferably, the antibody is CE5 or GB3.

Monoclonal antibodies are preferred. Preferably, it is an antibody or fragment or derivative thereof having an IgG, IgE, IgM or IgA isotype. Preferably, the antibody is human or humanized, but may also be of other

- 16 -

origin, such as animal origin, in particular of mouse or camel origin. The antibody may be in various forms, such as a single chain antibody, bi- or tri-functional or multi-functional antibody, Fab- of Fab₂-fragment or as entire antibody in which the Fc-fragment has a modified affinity towards Fc
5 receptors or complement. It may also be a Fab fragment, a F(ab)₂ fragment, or a Fv fragment, or an scv fragment.

The antibody or fragment or derivative thereof may also be a recombinantly produced polypeptide or polypeptide analogue which has a specific binding
10 region comprising the sequence of the CDRs or a similar sequence related to more than 50 %, preferably more than 70 %, preferably more than 90 %, preferably more than 95 % to the provided sequences. These sequences may also be the starting point for the design of inhibitors of Fc-receptors. Therefore, also peptidomimetica are part of the invention that use or mimic
15 sequence motives of the provided CDRs.

In another preferred embodiment, the antibody or fragment or derivative thereof is an anticaline or lipocaline-variant or another antibody surrogate.

20 The obtained antibody or fragment or derivative thereof can be coupled to an effector molecule such as an antigen of interest, antibodies, antibody fragments, marker molecules, cytotoxic substances, sterically bulky blocking substances and linker molecules and linker substances.

25 Another aspect of the invention are nucleic acids, vectors and host cells containing nucleic acids encoding the peptides and/or the antibodies or fragments or derivatives thereof, of the present invention as described above.

30 From the antibody or fragment or derivative thereof according to the invention, a nucleic acid sequence encoding this protein can be derived. Preferably, that sequence encodes the variable regions, preferably the CDRs binding to the above mentioned epitopes of FcγRIIb. Most preferably,

- 17 -

the nucleic acid sequence encodes the CDRs according to one or more of the sequences according to Figures 5 and 6. Preferably, the nucleic acid encodes the sequence of monoclonal antibodies CE5 or GB3.

5 The nucleic acid sequence may be inserted into a vector for the expression of the protein according to Figures 5 and 6, which vector is also an aspect of the present invention. The vector preferably comprises a promoter under the control of which the above nucleic acid sequences are placed. The vector can be prokaryotic or an eukaryotic expression vector, where the
10 recombinant nucleic acid is either expressed alone or in fusion to other peptides or proteins or a vector suitable for DNA-vaccination.

The invention also provides a host cell transfected with the vector mentioned above. The host cell can be any cell, a prokaryotic cell or a eukaryotic cell.

15 The present invention further provides a pharmaceutical composition useful for the treatment of diseases associated with Fc receptor mediated signaling, comprising an effective amount of the antibody or fragment or derivative thereof according to the invention, and pharmaceutically
20 acceptable carrier substances.

The present invention further provides a diagnostic kit for the detection of autoimmune diseases and/or cancer, comprising an antibody or fragment or
25 derivative thereof according to the invention and/or the recombinant peptide or polypeptide according to the invention which comprises or represents one of the epitopes as described herein, and optionally marker reagents, carrier reagents and/or suitable receptacles.

30 Immunization with unglycosylated correctly folded Fc-receptors, e.g. derived from *E. coli*, and decorated with the described epitopes surprisingly leads to antibodies that specifically recognize natural Fc-receptors expressed on blood cells and in cell culture (Figure 3 and Figure 4).

- 18 -

Another aspect of the present invention is a method of producing antibodies characterized by the ability to specifically bind to Fc γ R11b, wherein the method comprises:

- 5 (a) Providing the correctly folded Fc γ R11b molecule or portion thereof as an immunogen, comprising at least a part of the extracellular domain (conformational epitopes), their conjugation, or conjugation with other carrier molecules (e.g. KLH, BSA).
- (b) Immunizing a mammal with the immunogen of (a) and producing antibodies according to known methods,
- 10 (c) Isolating the resulting antibodies or the cells producing these antibodies.

The antibodies are preferably monoclonal antibodies.

15 The CDRs may be grafted to other immunoglobulin classes (e.g. IgM, IgE, IgG1-IgG4) or other scaffolds (e.g. lipocaline-variants, camel antibodies), or mutated or derivatised molecules (e.g. engineered antibodies containing a modified Fc-fragment).

20 The above described method may be used to produce vehicles for the immunization of animals and results in an anti-serum of increased specificity towards Fc γ R11b, which after fusion of isolated B-cells with myeloma cells results in hybridoma cells with an increased fraction producing antibodies specific for Fc γ R11b.

25 The antibody or fragment or derivative thereof according to the present invention is useful for the production of a medicament for the treatment and/or diagnosis of conditions involving the immune system. Preferably, these conditions are autoimmune diseases or cancer.

30 The diseases that can be treated with a medicament of the invention include, but are not limited to rheumatoid arthritis, psoriatic arthritis,

- 19 -

ankylosing spondylitis, Reiter's syndrome, psoriasis, multiple sclerosis, lupus erythematosus.

5 Autoimmune diseases which can be diagnosed or treated using the substances of the present invention include, but are not limited to systemic lupus erythematosus, rheumatoid arthritis, Multiple Sclerosis, idiopathic thrombocytopenic purpura and host-versus-graft disease.

10 Surprisingly, it has been found by the present inventors that it is possible to enhance certain immunological processes by using the FcγRIIb-binding substances in vivo. In particular, it is possible to use those substances of the invention to specifically block the signaling of FcγRIIb on cells and thereby increasing the immune response of the individual. This may be used to increase ADCC against tumor cells. In practice the FcγRIIb-binding
15 substance is given as adjuvant with a therapeutic antibody. The inhibitory signal transmitted by antigens (e.g. tumor cells) opsonized with the therapeutic antibody to activated macrophages or B-cells is blocked and the host immune system will be more effective in combating the targeted antigen. This can either be in a direct way by labeling tumor cells that
20 express FcγRIIb (e.g. B cell lymphoma) or by using this FcγRIIb-binding substance as adjuvant in all approaches which use known therapeutic antibodies and therefore depend on the ADCC of the host.

25 The known therapeutic antibodies include but are not limited to Herceptin®, Rituxan®, IC14, PANOREX™, IMC-225, VITAXIN™, Campath 1H/LDP-03, LYMPHOCIDE™ and ZEVLIN™. They can also include antibodies binding to the following cancer antigens: MAGE-1, MAGE-3, BAGE, GAGE-1, GAGE-2, N-acetylglucosaminyltransferase, p15, beta-catenin, MUM-1, CDK-4, HER-2/neu, human papillomavirus E6, human papillomavirus E7 and MUC-1.

30

In certain lymphomas B-cells or Mast-cells are transformed. The antibody or fragment or derivative thereof is able to cross link FcγRIIb on the surface of

- 20 -

these cells, which labels these cells for elimination but additionally an inhibitory and pro apoptotic signal is transmitted to these cells. This effect is an improvement of previous therapeutic antibody approaches, which completely depend on the ADCC of the host (e.g. Rituxan).

5

The same antibody that crosslinks or blocks Fc-receptors may be used for the treatment of host-versus-graft disease or amyloid associated diseases.

10 The same Fc γ RIIb blocking and/or cross linking constructs maybe used to inhibit mast cells for the treatment of allergies.

15 The antibody or fragment or derivative thereof maybe coupled to IgE (e.g. by transferring the CDRs shown in figure 5 or 6 to an IgE molecule). In this case the IgE is bound by the Mast-cell expressed Fc ϵ RI and the Fc γ RIIb specific CDRs cross link the ITAM of Fc ϵ RI with the ITIM of the Fc γ RIIb. Again an inhibitory and/or apoptotic signal is transmitted to Mast-cells, which is useful in the therapy of allergies.

20 The antibody or fragment or derivative thereof (e.g derivatives of the sequences depicted in figures 5 and 6) maybe used for the treatment of autoimmune diseases.

25 Such substances inhibit B-cells, dendritic cells and activated granulocytes (e.g Macrophages) which leads to a reduced production of immune stimulatory mediators and to a reduction in antibody production as well as antigen presentation (e.g. on Dendritic Cells and Macrophages leading to a decrease in T-cell recruitment). Taken together the feed back loop of antibody production and restimulation of the immune system is inhibited.

30 Preferably the anti- Fc γ RIIb or Fc γ RIIa does not interfere with Fc-fragment binding of the receptor. In this way the normal function of the Fc-receptor is in contrast to blocking antibodies maintained and enhances the activation of the cell by the additional recruitment of further receptors.

- 21 -

On the other hand specific anti- FcγRIIa antibodies or fragments thereof maybe used in diabodies to direct an antigen towards this receptor or fragments of these antibodies maybe used to inhibit the uptake of immune complexes for example for the treatment of ITP.

The CDRs can be used alone or in combination for the production of specific inhibitors of the FcγRIIa/IgG interaction or the FcγRIIb/IgG interaction. For the generation of such inhibitors, derivatives or peptidomimetics as well as non-natural amino acids may be used.

The inhibitors may in turn be used to generate crystal structures or for structure based design or as subject for evolutionary methods. A further use is the generation of modified sequences from that depicted in figures 5 or 6 by evolutionary methods (e.g. random or site directed mutagenesis or structure based design).

In particular, the inhibitors of Fc receptors may be used to reduce or enhance the specificity of the above for the selected Fc-receptors. To this end, modifications can be carried out in the CDRs of the specific antibodies, in particular of GB3 and CE5, in order to enhance or lower their specificity to FcγRIIb.

The peptides and polypeptides and substances of the invention, in particular the antibody or fragment or derivative thereof are useful for the production of a medicament for the treatment and/or diagnosis of conditions involving the immune system, in particular autoimmune diseases, preferably those selected from Systemic Lupus Erythematosus, Rheumatoid Arthritis, Immune Thrombocytopenic Purpura or Multiple Sclerosis. Further uses of the peptides and antibodies or fragments or derivatives thereof of the invention are in the diagnosis and/or treatment of cancer and/or allergies. The mAbs CE5 or GB3 or derivatives or fragments thereof are particularly useful for the treatment of autoimmune diseases, Multiple sclerosis, Systemic Lupus

- 22 -

Erythematosis, Idiopathic Thrombocytopenic Purpura, Rheumatoid Arthritis, and cancer, in particular lymphomas or leukemias.

5 The mAbs CE5 or GB3 or derivatives or fragments thereof can also be used for the treatment of cancer in combination with other therapeutics preferably biotherapeutics (e.g. antibodies).

10 The antibody or derivatives or fragments thereof generated according to the present invention can be used for the treatment and/or diagnosis of cancer, preferably in combination with other therapeutics, preferably biotherapeutics (e.g. further antibodies). The antibody or fragment or derivative thereof is then preferably used as an adjuvant.

15 Further uses of the antibody or fragment or derivative thereof of the invention include the use for the production of pharmaceutical and/or diagnostic compositions for the treatment of host-versus-graft disease, for the treatment of amyloid linked diseases or to increase the effect of vaccination or for the treatment of diseases associated activated dendritic cells and/or macrophages.

20

It is also possible to use an antibody or fragment or derivative thereof which comprises specific anti- FcγRIIIa fragments in bi-specific antibodies to direct antigens towards transport by thrombocytes and/or uptake by the liver and spleen phagocytosis system. Preferably, the antibody or fragment or
25 derivative thereof is a specific anti-FcγRIIIa antibody or fragment thereof for the treatment of ITP.

Description of Figures and Sequence Listing

30

Figure 1:

Sequence alignment of the extracellular domains of the human FcγRIIIb and FcγRIIIa. Differing amino acids are boxed.

- 23 -

Figure 2:

Structure of FcγRIIb in ribbon representation. The unique residues are shown in ball-and-stick and potential glycosylation sites are indicated as larger spheres. Arrows point to possible extractable substructures (epitopes 1 and 2) that may be artificially generated for the improvement of immunization protocols towards specific FcγRIIb-antisera and subsequently for the production of isoform specific monoclonal antibodies.

Figure 3:

Left diagram: Histogram of a FACS measurement of Raji cells (FcγRIIb-positive and FcγRIIa-negative) using the preimmune serum of the mouse (minus), the obtained antiserum after the immunization procedure (antiserum) and the pan-FcγRII-mAb AT10 (Greenman et al., 1991). Right diagram: Fluorescence label on U-937 cells (FcγRIIa-positive and FcγRIIb negative). The antiserum reacts only marginally with the cells indicating the presence of specific antibodies.

Figure 4:

FACS analysis of human blood incubated either with normal serum (negative control), antiserum of a mouse immunized with FcγRIIb-CDE[126-137], mAb AT10 or the specific monoclonal antibody GB3 generated by using this invention. a): Dotblot analysis of the blood sample in terms of cell size (FSC-H) and granularity (SSC-H). The observed regions R1, R2 R3 contain lymphocytes (B and T cells), monocytes and granulocytes respectively. b) Fluorescence intensity of the cells found in region R1 representing lymphocytes. The pan-FcγRIIb mAb AT10, the mAb GB3 and the antiserum stain the FcγRIIb-positive B-cells while the FcγRII-negative T cells are not recognized. c) Fluorescence intensity of the cells found in region R2 representing monocytes/macrophages. In contrast to the positive controls mAb AT10 and the antiserum the mAb GB3 does not recognize the FcγRIIa-positive monocytes. d) Fluorescence intensity of the cells found in region R3 representing granulocytes. In contrast to the positive controls mAb AT10 and

- 24 -

the antiserum the mAb GB3 does not recognize the FcγR11a-positive granulocytes.

Figure 5:

5 The variable regions of the cloned antibody GB3. The boxed regions represent the CDRs while the underlined termini may vary due to cloning artifacts introduced by the primer. a) Variable region of the light chain; b) Variable region of the heavy chain.

10 Figure 6:

The variable regions of the cloned antibody CE5. The boxed regions represent the CDRs while the underlined termini may vary due to cloning artifacts introduced by the primer. a) Variable region of the light chain; b) Variable region of the heavy chain.

15

Figure 7:

The glycopeptide CDE[126-137] used for immunization and generation of FcγR11b-specific antibodies.

20 Figure 8:

Immunisation of SJL mice with a specific anti-mouse FcγR11 antibody. SJLj were immunized with 200μg MOG an day 0. Treatment with antiFcγR11 antibody (dosis of 50μg/week) started at day 5. The clinical score was monitored daily and is given as the average of the 8 mice per group.

25

SEQ ID NO: 1 amino acid sequence of FcγR11a (as in Fig. 1)

SEQ ID NO: 2 amino acid sequence of FcγR11b (as in Fig. 1)

30 SEQ ID NO: 3 sequence of the glycopeptide CDE [126-137]

SEQ ID NO: 4 nucleic acid sequence of the variable light region of

- 25 -

mAb GB3

SEQ ID NO: 5 corresponding amino acid sequence of the variable light region of mAb GB3

5

SEQ ID NO: 6 nucleic acid sequence of the variable heavy region of mAb GB3

SEQ ID NO: 7 corresponding amino acid sequence of the variable heavy region of mAb GB3

10

SEQ ID NO: 8 nucleic acid sequence of the variable light region of mAb CE5

SEQ ID NO: 9 corresponding amino acid sequence of the variable light region of mAb CE5

15

SEQ ID NO: 10 nucleic acid sequence of the variable heavy region of mAb CE5

20

SEQ ID NO: 11 corresponding amino acid sequence of the variable heavy region of mAb CE5

25 Examples

Example 1

Synthesis of the Cyclo-[N- β -(2-acetylamino-deoxy-2- β -glucopyranosyl)-Asn¹³⁸, Gly¹⁴¹]- (129-141)-Fc γ RIIb2, CDE[126-137]

30

Standard amino acid derivatives were from Alexis (Läufelfingen, Switzerland), Fluorenylmethoxycarbonyl-derivative (Fmoc) of Asn(N- β -3,4,6-tri-O-acetyl-2-acetylamino-deoxy-2- β -glucopyranosyl)-OH from Merck-

- 26 -

Novabiochem (Darmstadt, Germany), and the preloaded chlorotriyl resin from Pepchem (Tübingen, Germany). Reagents and solvents were of the highest quality commercially available and were used without further purification. Analytical reversed-phase HPLC was performed on Waters equipment (Eschborn, Germany) with a Symmetry C₁₈ column (5 μm, 3.9x150 mm, Waters) by linear gradient elution: (1) 0-100 % A in 15 min, or (2) 0-30 % A in 20 min, up to 50 % A in 5 min and to 100 % A in further 5 min, (flow rate of 1.5 ml/min and UV detection at 210 nm). The binary elution system was (A) acetonitrile/2 % H₃PO₄ (90:10) and (B) acetonitrile/2 % H₃PO₄ (5:95). Preparative reversed-phase HPLC was carried out on Abimed equipment (Langenfeld, Germany) using Nucleosil C₁₈ PPN (5 μm, 100 Å, 10x250 mm, Macherey-Nagel, Düren, Germany) and a gradient of 0.08 % trifluoroacetic acid (TFA) in acetonitrile (A) and 0.1 % TFA in water (B) at a flow rate of 10 ml/min: 2 % A for 7 min, up to 40 % A in 50 min and to 70 % A in further 5 min. ESI-MS spectra were recorded on a Perkin-Elmer SCIEX API 165 triple quadrupole spectrometer. LC-MS was carried out with a Nucleosil C₁₈ column (5 μm, 100 Å, 1x250 mm, Macherey-Nagel) using linear gradients of 0.1 % TFA in water and 0.08 % TFA in acetonitrile (flow rate: 30 μl/min; detection at 210 nm).

20

a) Solid-Phase Peptide Synthesis.

The linear peptide precursor was synthesized manually on Fmoc-Gly-chlorotriyl resin (232 mg, 0.13 mmol) following standard procedures of Fmoc/*tert*-butyl (tBu) chemistry. The Fmoc group was cleaved in each step with two successive treatments (3 and 20 min) with 20 % piperidine in *N*-methyl pyrrolidone (NMP). For Fmoc-Ser(tBu)-OH and Fmoc-Phe-OH double couplings (2x1 h) with Fmoc-amino acid/2-(1*H*-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluoro-phosphate (HBTU)/*N*-hydroxybenzotriazole (HOBt)/*N,N*-diisopropylethylamine (DIEA) (4:4:4:8 eq) in NMP were applied, whereas the glycosylated Asn derivative was introduced by single coupling using Fmoc-aminoacid/(1*H*-benzotriazol-1-yloxy)-tripyrrolidinophosphonium

30

- 27 -

hexafluorophosphate (PyBOP)/HOBt/DIEA (2:2:2:5 eq) in NMP. The reaction was complete after 5 h, as confirmed by the Kaiser test. A capping step with acetic anhydride/DIEA (1:1, 3 eq) for 10 min was performed prior to chain elongation. For acylation with the remaining amino acid derivatives (Arg was introduced as Arg-2,2,4,6,7-pentamethyl-dihydrobenzofurane-5-sulfonyl [Pbf] derivative) again double couplings (2x1.5 h) were used with Fmoc-amino acid/HBTU/HOBt/DIEA (6:6:6:12 eq) in NMP.

b) Cleavage of the Side-Chain-Protected Peptide.

10

The side-chain-protected linear peptide was cleaved from the resin by treating the peptide-resin with 5 ml of 1 % TFA in dichloromethane (DCM) for 3 min. The filtrate was analyzed by thin layer chromatography (TLC) (CH₂Cl₂/MeOH/H₂O, 8:3:1) prior to addition of 1 ml of 10 % pyridine in methanol. The TFA treatment was repeated until the TLC control on the filtrate was negative (overall four treatments). Finally, the resin was washed with DCM and trifluoroethanol to improve the peptide recovery. The peptide-containing filtrates and the final washes were combined and concentrated to a small volume. The residue was diluted with MeOH, and the product was precipitated with ice-cold water. The crude product was collected by filtration (270 mg, 80 % yield) and characterized by analytical HPLC (gradient 1) and ESI-MS. A major peak (*t_R* 9.5 min; ESI-MS: *m/z* = 2520 [M+H]⁺; *M_r* = 2519.0 calcd for C₁₂₀H₁₈₈N₂₀O₃₆S) and a minor peak (*t_R* 9.3 min; ESI-MS: *m/z* = 2478 [M-42+H]⁺) at the ratio of 75:20 were found to correspond to the expected product and to a side product, respectively. The mass difference was attributed to the loss of one acetyl protecting group from Asn(Ac₃AcNH-β-Glc).

15

20

25

c) Cyclization.

30

Backbone cyclization was accomplished at a peptide concentration of 0.9 mM in *N,N*-dimethylformamide (DMF), in the presence of PyBOP/HOBt/DIEA (1.5:1.5:3.5 eq). The base was added in portions over 1 h. The conversion of

- 28 -

the linear peptide to the cyclic form was monitored by analytical HPLC, and was completed after 2.5 h. The reaction mixture was taken to dryness, and the residue was triturated and washed with ice-cold diethyl ether to remove traces of DMF prior to the TFA cleavage.

5

d) Cleavage of the Side-Chain Protecting Groups.

The acid-labile side-chain protecting groups were removed by dissolving the cyclic peptide in 10 ml the ice-cold TFA/triisopropylsilane (TISH)/H₂O (90:5:5). After 2 h shaking, the TFA was removed under reduced pressure, the oily residue was diluted with a small amount of MeOH and the crude product precipitated with ice-cold diethyl ether. The precipitate was collected by centrifugation, washed several times with ice-cold ether and, finally, lyophilized from water. The crude glycopeptide which in addition to the triacetylated form, according to LC-MS was contaminated by the di- and mono-acetyl derivatives, was suspended in MeOH and treated in portions with NaOMe over 30 min until an apparent pH of > 10 was reached. The reaction was monitored by HPLC, and after 3.5 h it was quenched by addition of glacial acetic acid until pH < 5. The mixture was taken to dryness, and the solid was suspended in MeOH and reprecipitated with ice-cold diethyl ether. The precipitate was collected by filtration and lyophilized from water. The crude product was purified by preparative HPLC and the cyclic glycopeptide was isolated as lyophilized material; yield: 20 % yield (based on the starting resin loading of 0.13 mmol); HPLC: > 95 % (*t_R* 7.37 min with gradient 2); ESI-MS: *m/z* = 1642.8 [M+H]⁺; M = 1641.8 Da calculated for C₇₁H₁₀₈N₂₀O₂₅.

Coupling of the CDE[126-137] to FcγRIIb yielding FcγRIIb-CDE[126-137]

100 μl human soluble FcγRIIb (10.6 mg/ml) were added to 1490 μl 50 mM borate pH 10 and 410 μl of the glycopeptide CDE[126-137] (2 mg/ml) and stirred gently at room temperature. 100 μl of a 0.3% glutaraldehyde solution were slowly added and the whole mixture stirred for another two hours at RT

- 29 -

before 100µl 1M glycine was added. The resulting FcγRIIb-CDE[126-137] was stirred for another 30min and then dialyzed against PBS and concentrated.

5 **Example 2**

Immunization with FcγRIIb-CDE[126-137]

A female six weeks old C57B1/6 mouse was immunized intraperitoneally every two weeks with an emulsion of 50µg FcγRIIb-CDE[126-137] in 100µl Complete Freund's Adjuvant (CFA, Sigma/Deisenhofen, Germany) for three
10 times. Three weeks after the last immunization the mouse was boosted with 50µg of the FcγRIIb-CDE[126-137]: Three days later the spleen was removed from the animal and the fusion of the extracted cells with myeloma cells was performed according to Bazin, and Lemieux, 1989.

15

Example 3

Screening of the hybridoma for FcγRIIb-CDE[126-137]-specificity

Clones that were able to grow in the presence of hypoxanthine, aminopterin,
20 and thymidine were isolated and their supernatant tested in ELISA assays where FcγRIIb-CDE[126-137] was precoated on microtitre plate with 120 ng sFcγRIIa/b per well (in 100 µl PBS, 20 °C, 12h). The plate was washed and incubated with PBS/T (PBS/0.2 % Tween20, 30 min). 100µl of the respective hybridoma were added to the well (100 µl, 90 min). The plate was washed
25 three times with blocking buffer before 100µl of a peroxidase labeled goat-anti mouse IgG+IgM antibody (Dianova, Hamburg/Germany) diluted in PBS/T was added. After incubating for 90 min and subsequent washing with PBS/T, 100 µl of substrate buffer (0.2 M citrate/phosphate buffer pH 5.2, 4 mg/ml o-phenylenediamine, 0.024 % (v/v) hydrogenperoxide) were applied
30 to the wells. The reaction was stopped by adding 50 µl 8 N sulfuric acid and the absorbance at 490 nm was measured in an ELISA reader.

- 30 -

Clones that were positive in this assay were tested by flow cytometry (FACS) using 10^5 Raji cells per sample (ATCC CCL-86) which strongly express human Fc γ RIIb. After incubation with 100 μ l hybridoma supernatant for 30 min on ice the cells were washed with 1 ml RPMI/10% FCS and precipitated by centrifugation (400 x g, 4 °C, 5 min). 100 μ l FITC labeled goat anti human antibody (Dianova, Hamburg/Germany) were added. After incubation for 30 min on ice the cells were washed (RPMI/10 % FCS) and subjected to flow cytometry (FACSort, Becton Dickinson, Heidelberg/Germany). The median value of the fluorescence for 5,000 counted cells was determined for each sample. Hybridoma supernatants that were positive in this assay were subjected in a similar assay using U-937 cells (ATCC CRL-1593.2) which strongly express Fc γ RIIa to determine Fc γ RIIb-specificity of the hybridoma. As positive control for both cell lines the pan-Fc γ RII-mAb AT10 (Greenman et al., 1991) was used.

15

Example 4

Immunisation of SJL mice with a specific anti-mouse Fc γ RII antibody

SJL-Mice were immunized with 200 μ g MOG to induce Experimental Autoimmune Encephalomyelitis (EAE) an established animal model of Multiple Sclerosis. Prophylactic as well as therapeutic (data not shown) treatment of 8 mice per group with a specific anti-mouse Fc γ RII antibody (50 μ g/ week) significantly reduces the symptoms (clinical score)of the disease (0=healthy,1=light paralysis,2=medium paralysis, 3=strong paralysis, 4=complete paralysis, 5=death). The results are shown in Figure 8.

25

References

- Amigorena, S., Bonnerot, C., Drake, J.R., Choquet, D., Hunziker, W., Guillet, J.G., Webster, P., Sautès, C., Mellman, I., Fridman, W.H. (1992),
5 Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes, *Science* 256, 1808-1812.
- Bazin, R. and Lemieux, R. (1989), Increased proportion of B cell hybridomas secreting monoclonal antibodies of desired specificity in cultures containing macrophage-derived hybridoma growth factor (IL-6). *J. Immunol. Methods*
10 116, 245-249.
- Ceuppens, J.L., Baroja, M.L., van Vaeck, F., Anderson, C.L. (1988), Defect in the membrane expression of high affinity 72kD Fc γ receptors on phagocytic cells in four healthy subjects, *J. Clin. Invest.* 82, 571-578.
- Clynes, R.A., Towers, T.L., Presta, L.G., Ravetch, J.V. (2000), Inhibitory Fc receptors modulate *in vivo* cytotoxicity against tumour targets. *Nature Medicine* 6, No. 4, 443-446.
15
- Engelhardt, W., Geerds, C., Frey, J. (1990), Distribution, inducibility and biological function of the cloned and expressed human γ Fc receptor II, *Eur. J. Immunol.* 20, 1367-1377.
- Fridman, W.H., Bonnerot, C., Daeron, M., Amigorena, S., Teillaud, J.-L., Sautès, C. (1992), Structural bases of Fc γ R functions, *Immunol. Rev.* 125, 49-76.
20
- Fridman, W.H., Teillaud, J.-L., Bouchard, C., Teillaud, C., Astier, A., Tartour, E., Galon, J., Mathiot, C., Sautès, C. (1993), Soluble Fc γ receptors, *J. Leukocyte Biol.* 54, 504-512.
25
- Greenman, J., Tutt, A.L., George, A.J., Pulford, K.A., Stevenson, G.T., Glennie, M.J. (1991), Characterization of a new monoclonal anti-Fc gamma RII antibody, AT10, and its incorporation into a bispecific F(ab')₂ derivative for recruitment of cytotoxic effectors. *Mol. Immunol.* 28, 1243-1254.
- Homsy, J., Meyer, M., Tateno, M., Clarkson, S., Levy, J.A. (1989), The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells, *Science* 244, 1357-1360.
30

- 32 -

Isakov N. (1997), ITIMs and ITAMs. The Yin and Yang of antigen and Fc receptor-linked signaling machinery. *Immunol Res.* 16, 85-100.

Littaua, R., Kurane, I. and Ennis, F.A. (1990), Human IgG Fc γ R II mediates antibody-dependent enhancement of dengue virus infection, *J. Immunol.* 144, 3183-3186.

Metzger, H. (1992A), Transmembrane signaling: The joy of aggregation, *J. Immunol.* 149, 1477-1487.

Metzger, H. (1992B), The receptor with high affinity for IgE, *Immunol. Rev.* 125, 37-48.

Poo, H., Kraus, J.C., Mayo-Bond, L., Todd, R.F., Petty, H.R. (1995), Interaction of Fc γ RIIB with complement receptor type 3 in fibroblast transfectants: evidence from lateral diffusion and resonance energy transfer studies, *J. Mol. Biol.* 247, 597-603.

Ravanel, K., Castelle, C., Defrance, T., Wild, T.F., Charron, D., Lotteau, V., Roubourdincombe, C. (1997), Measles virus nucleocapsid protein binds to Fc γ RII and inhibits human B cell antibody production. *J. Exp. Med.* 186, 269-278.

Ravetch, J. V. and Bolland, S. (2001), IgG Fc Receptors. *Annu. Rev. Immunol.* 19, 275-290.

Sondermann, P., Jacob, U., Kutscher, C., Frey J. (1999A), Characterization and crystallization of soluble human Fc γ receptor II (CD32) isoforms produced in insect cells. *Biochemistry.* 38, 8469-8477.

Sondermann, P. and Jacob, U. (1999B), Human Fc γ receptor IIb expressed in *E. coli* reveals IgG binding capability. *Biol Chem.* 380, 717-721.

Sondermann P, Huber R, Oosthuizen V, Jacob U. (2000), The 3.2Å crystal structure of the human IgG1 Fc fragment-Fc γ RIII complex. *Nature* 406, 267-273.

Sondermann P, Kaiser J, Jacob U. (2001), Molecular basis for immune complex recognition: a comparison of Fc-receptor structures. *J Mol Biol.* 309, 737-749.

- 33 -

van de Winkel, J.G.J. and Capel, P.J.A. (1993), Human IgG Fc receptor heterogeneity: Molecular aspects and clinical implications, *Immunol. Today* 14, 215-221.

5 Yang, Z., Delgado, R., Xu, L., Todd, R.F., Nabel, E.G., Sanchez, A., Nabel, G.J. (1998), Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins, *Science* 279, 983-984.

Zhou, M.-J., Todd, R.F., van de Winkel, J.G.J., Petty, H.R. (1993), Cocapping of the leukoadhesin molecules complement receptor type 3 and lymphocyte function-associated antigen-1 with Fc γ RIII on human neutrophils.
10 Possible role of lectin-like interactions, *J. Immunol.* 150, 3030-3041.

DEMANDES OU BREVETS VOLUMINEUX

**LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.**

CECI EST LE TOME __1__ DE __2__

NOTE: Pour les tomes additionels, veuillez contacter le Bureau Canadien des Brevets.

JUMBO APPLICATIONS / PATENTS

**THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.**

THIS IS VOLUME __1__ OF __2__

NOTE: For additional volumes please contact the Canadian Patent Office.

- 34 -

Claims

- 5 1. An artificial peptide or polypeptide comprising a conformationally discriminating epitope (CDE) in its native conformation, wherein the CDE is structurally stabilized by circularization.
2. The peptide or polypeptide claim 1, wherein it comprises artificial or/and glycosylated amino acids.
- 10 3. The peptide or polypeptide claim 1 or 2, wherein it is conjugated to a carrier molecule.
4. The peptide or polypeptide of any one of the preceding claims, wherein
15 it comprises a CDE of an Fc receptor.
5. The peptide or polypeptide of claim 4, wherein it comprises a CDE of FcγRIIb or FcγRIIa, the CDE comprising at least residue which is unique to either FcγRIIb or FcγRIIa.
- 20 6. The peptide or polypeptide of claim 5, wherein the CDE comprises amino acids 27 to 30, and/or amino acids 127 to 135, and/or 160 to 171 of FcγRIIb according to SEQ ID NO: 2 or the corresponding amino acids of FcγRIIa according to SEQ ID NO: 1, or the amino acid
25 sequence according to SEQ ID NO: 3.
7. The peptide or polypeptide of any one of claims 4 to 6, wherein it is conjugated to FcγRIIb or FcγRIIa.
- 30 8. A method of producing a peptide carrying a conformationally discriminating epitope (CDE) for the generation of antibodies specifically recognizing a protein of interest carrying such an epitope,

- 35 -

wherein the method comprises:

- (a) providing a protein of interest,
- (b) identifying a CDE on that protein,
- (c) producing a peptide comprising the sequence of the CDE,
- 5 (d) structurally stabilizing the peptide by circularization so that the CDE is present in its native conformation.

9. The method of claim 8, wherein the circularization of the peptide is achieved by generating cysteine bridges, bridging amino acid side chains that form a pseudopeptide.

10. The method of claim 8 or 9, wherein the peptide is generated using amino acids carrying glycosylation moieties which are present on the protein of interest.

11. The method of any one of the preceding claims 8 to 10, wherein it comprises the step:
(e) conjugating the peptide to a carrier molecule selected from haptens, polypeptides, peptides, and the protein of interest.

12. A peptide or polypeptide comprising a CDE, obtainable by the method of any one of claims 8 to 11.

13. Use of a peptide or polypeptide of any one of claims 1 to 7 as an immunogen for the generation of immunomodulatory substances specifically recognizing the CDE in its natural environment.

14. Use of a peptide or polypeptide of any one of claims 1 to 7 for the immunisation of animals or transgenic animals expressing human FcγRIIa or FcγRIIb.

15. Use of a peptide or polypeptide of any one of claims 1 to 7 for the generation of antibodies that can specifically recognize alleles of the

- 36 -

FcγRIIIa Arg/His polymorphism at position 131 or the FcγRIIIa Val/Phe polymorphism at position 155.

- 5 16. A method of producing substances capable of discriminating between an antigen of interest and closely related antigens, wherein the method comprises immunising an animal with a peptide or polypeptide according to any one of claims 1 to 7 or/and with a correctly folded peptide derived from FcγRIIb or FcγRIIIa, and isolating the resulting antibodies, and optionally using the antibodies to generate
- 10 recombinant immunomodulatory substances.
17. A substance characterized by the ability to specifically bind to the peptide or polypeptide of any one of claims 1 to 7.
- 15 18. An antibody or fragment or derivative thereof, wherein it specifically binds to human FcγRIIb or FcγRIIIa in the natural environment of the Fc receptor.
19. The antibody of claim 18, wherein it binds with higher affinity to FcγRIIb
- 20 than to FcγRIIIa, preferably with at least 10fold, more preferably at least 100fold, more preferably at least 1,000fold, more preferably at least 10,000fold, more preferably at least 100,000fold, more preferably at least 1,000,000fold higher affinity to FcγRIIb than to FcγRIIIa.
- 25 20. The antibody of claim 18, wherein it binds with higher affinity to FcγRIIIa than to FcγRIIb, preferably with at least 10fold, more preferably at least 100fold, more preferably at least 1,000fold, more preferably at least 10,000fold, more preferably at least 100,000fold, more preferably at least 1,000,000fold higher affinity to FcγRIIIa than to FcγRIIb.
- 30 21. The antibody or fragment or derivative thereof of claim 18, 19 or 20 wherein it is able to specifically block IgG binding to human FcγRIIb or

- 37 -

FcγRIIa.

- 5 22. The antibody or fragment or derivative thereof of any one of claims 18 to 21, wherein it does not interfere with immune complex binding to FcγRIIb or FcγRIIa.
- 10 23. The antibody or fragment or derivative thereof of claim 18, 19, 20 or 21, wherein it is capable of inhibiting the physiological function of human FcγRIIb or FcγRIIa.
- 15 24. The antibody or fragment or derivative thereof of claim 18, 19, 20 or 22, wherein it is capable of activating the physiological function of human FcγRIIb or FcγRIIa.
- 20 25. The antibody or fragment or derivative thereof of claim 18, 19, 20, 22 or claim 24, wherein it is able to specifically cross-link human FcγRIIb or FcγRIIa.
- 25 26. The antibody or fragment or derivative thereof of any one of claims 18 to 25, wherein it occurs in a monomeric or multimeric state.
27. The antibody or fragment or derivative thereof of any one of claims 18 to 26, wherein it is capable of binding to a CDE of FcγRIIb or FcγRIIa.
- 30 28. The antibody or fragment or derivative thereof of claim 27, wherein it is capable of binding to an epitope of human FcγRIIb or FcγRIIa comprising at least one of amino acids 12, 27, 29, 30, 104, 127, 132, 135, 160 and 171 of the amino acid sequence of FcγRIIb or FcγRIIa according to SEQ ID NO: 1 or SEQ ID NO: 2.

- 38 -

29. The antibody or fragment or derivative thereof of claim 28, wherein it is capable of binding to an epitope of FcγRIIb or FcγRIIa comprising amino acids 27 to 30, and/or 127 to 135, and/or 160 to 171 of the amino acid sequence of FcγRIIb or FcγRIIa according to SEQ ID NO: 1 or SEQ ID NO: 2.
30. The antibody or fragment or derivative thereof of any one of claims 18 to 29, wherein it is a polypeptide carrying a complementarity determining region (CDR) which is specific for FcγRIIb.
31. The antibody or fragment or derivative thereof of claim 30, wherein it is a polypeptide carrying one or more of the CDR-sequences according to SEQ ID Nos: 5, 7, 9 and 11.
32. The antibody or fragment or derivative thereof of any one of claim 18 to 31, wherein it is of the class IgG, IgE, IgM or IgA.
33. The antibody or fragment or derivative thereof of any one of claims 18 to 32, wherein it is selected from single chain antibodies, bi-functional antibodies and tri-functional antibodies, Fab fragments, F(ab)₂ fragments, Fv fragments and scv-fragments.
34. An antibody or part hereof, according to any one of claims 18 to 33, characterised in comprising the variable light and/or heavy regions of antibody GB3 according to SEQ ID NO: 5 and 7, or a portion thereof having specificity; or the variable light and/or heavy regions of antibody CE5 according to SEQ ID NO: 9 and 11 or a portion thereof having specificity.
35. A nucleic acid sequence encoding the peptide of any one of claims 1 to 7 or the antibody or fragment or derivative thereof according to any one of the claims 18 to 34.

- 39 -

36. The nucleic acid of claim 35 encoding the sequence of monoclonal antibodies CE5 or GB3 according to SEQ ID NOs: 4, 6, 8 and 10 or a portion thereof.
- 5 37. A nucleic acid vector comprising the nucleic acid sequence according to claim 35 or 36.
38. A host cell transfected with a vector according to claim 37.
- 10 39. A pharmaceutical and/or diagnostic composition useful for the treatment and/or diagnosis of diseases associated with Fc receptor mediated signaling, in particular rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Reiter's syndrome, psoriasis or lupus erythematosus, comprising an effective amount of the antibody, fragment or derivative thereof according to any one of claims 18 to 34, and pharmaceutically acceptable carrier substances.
- 15 40. A diagnostic kit for the detection of autoimmune diseases and/or cancer, comprising the antibody, fragment or derivative thereof according to any one of claims 18 to 34 and/or the recombinant peptide or polypeptide according to any one of claims 1 to 7.
- 20 41. Use of the antibody or fragment or derivative thereof of any one of claims 18 to 34 for the production of inhibitors or activators of the FcγRIIa/IgG interaction or the FcγRIIb/IgG interaction.
- 25 42. Use of the antibody or fragment or derivative thereof of any one of claims 18 to 34 for the production of a pharmaceutical and/or diagnostic composition for the diagnosis and/or treatment of autoimmune diseases, Systemic Lupus Erythematosus, Rheumatoid Arthritis, Immune Thrombocytopenic Purpura or Multiple Sclerosis.
- 30 43. Use of the antibody or fragment or derivative thereof of any one of claims 18 to 34 for the production of a pharmaceutical and/or

- 40 -

diagnostic composition for the diagnosis and/or treatment of cancer, in particular lymphomas or leukemias.

- 5 44. Use of the antibody or fragment or derivative thereof of any one of claims 18 to 34 as an adjuvant with other biotherapeutics for the treatment and/or diagnosis of cancer.
- 10 45. Use of claim 44, wherein the other therapeutics are selected from the group comprising the antibodies Herceptin®, Rituxan®, IC14, PANOREX™, IMC-225, VITAXIN™, Campath 1H/LDP-03, LYMPHOCIDE™ und ZEVLIN™, and antibodies binding to the following cancer antigens: MAGE-1, MAGE-3, BAGE, GAGE-1, GAGE-2, N-acetylglucosaminyltransferase, p15, beta-catenin, MUM-1, CDK-4, HER-2/neu, human papillomavirus E6, human papillomavirus-E7 and MUC-1.
- 15 46. Use of the antibody or fragment or derivative thereof of any one of claims 18 to 34 for the production of a pharmaceutical and/or diagnostic composition for the diagnosis and/or treatment of allergies.
- 20 47. Use of the antibody or fragment or derivative thereof of any of claims 18 to 34 for the production of a pharmaceutical and/or diagnostic composition for the treatment of diseases associated activated dendritic cells and/or macrophages.
- 25 48. Use of the antibody or fragment or derivative thereof of any of claims 18 to 34 for the production of a pharmaceutical and/or diagnostic composition for the treatment of host-versus-graft disease.
- 30 49. Use of the antibody or fragment or derivative thereof of any of claims 18 to 34 for the production of a pharmaceutical and/or diagnostic composition for the treatment of amyloid linked diseases.
50. Use of the antibody or fragment or derivative thereof of any of claims

- 41 -

18 to 34, wherein the antibody or fragment or derivative thereof comprises specific anti- Fc γ R11a fragments in bi-specific antibodies to direct antigens towards transport by thrombocytes and/or uptake by the liver and spleen phagocytosis system.

5

51. Use of the antibody or fragment or derivative thereof of any of claims 18 to 34, wherein the antibody or fragment or derivative thereof is a specific anti-Fc γ R11a antibody or fragment thereof for the production of a pharmaceutical and/or diagnostic composition for the diagnosis and/or treatment of ITP.

10

52. Use of the antibody or fragment or derivative thereof of any of claims 18 to 34 for the production of a pharmaceutical composition to increase the effect of vaccination.

15

53. Antibody or fragment or derivative thereof of any one of claims 18 to 34, wherein it is modified in the Fc-fragment by the modification of the glycosylation and/or mutagenesis to enhance the binding towards subsets of the Fc-receptors.

20

Figure 2:





Figure 3:






Figure 4:

Figure 5:**a) Variable light region of mAb GB3**

agaattcagctgacccagctctccatcctccttattctgcctctctgggagaaagagtcagt
 R I Q L T Q S P S S L S A S L G E R V S

ctcacttgtcgggcaagtcaggaaattagtggttacttaagctggcttcagcagaaacca
 L T C R A S Q E I S G Y L S W L Q Q K P
 CDR1

gatggaactattaacgcctgatctacgccacatccgctttagattctgggtgtcccaaaa
 D G T I K R L I Y A T S A L D S G V P K
 CDR2

aggttcagtggcagtggtctgggtcaaattattctctcaccatcagcagccttgagtct
 R F S G S G S G S N Y S L T I S S L E S

gaagattttgcagactattactgtctacaatatgctaattatccgtacacggttcggaggg
 E D F A D Y Y C L Q Y A N Y P Y T F G G
 CDR3

gggaccaagctg
 G T K L

b) Variable heavy region of mAb GB3

gtgcagctgcagcagctctggacctgagctggtgaagcctggggcttcagtgaaagatttcc
 V Q L Q Q S G P E L V K P G A S V K I S

tgcaaggcttctggctacaccttcactgactactatatactggggtgaaacagtggcct
 C K A S G Y T F T D Y Y I Y W V K Q W P
 CDR1

ggacagggacttgagtggttggatgggatttttctggaactggtaataacttactacaat
 G Q G L E W I G W I F P G T G N T Y Y N
 CDR2

gaaaacttcaaggacaaggccacacttactatagatagatcctccagcacagcctacatg
 E N F K D K A T L T I D R S S S T A Y M
 CDR2 (contd.)

ttgctcggcagcctgacctctgaggactctgcggtctatttctggttatgggtccgtttgct
 L L G S L T S E D S A V Y F C Y G P F A
 CDR3

tactggggccaa
 Y W G Q
 CDR3

Figure 6:**Variable heavy region of mAb CE5:**

tgcaggagtcaggacctggcctgggtggcgccctcacagagcctgtccatcacatgcaccgtct
 L Q E S G P G L V A P S Q S L S I T C T V

cagggttctcattaaccggctatgggtgtaaactgggttcgccagcctccaggaaagggctctgg
 S G F S L T G Y G V N W V R Q P P G K G L

CDR1

agtggctgggaatgatttggggatgatggaaacacagactataattcagctctcaaattccagac
 E W L G M I W G D G N T D Y N S A L K S R

CDR2

tgagcatcagcaaggacaactccaagagccaagttttcttaaaaatgaacagtctgcacactg
 L S I S K D N S K S Q V F L K M N S L H T

atgacacagccaggtactactgtgccagagagagagattataggcttgactactggggccaag
 D D T A R Y Y C A R E R D Y R L D Y W G Q

CDR3

ggaccacggtcaccgtctcctcag
 G T T V T V S S

Variable light region of mAb CE5:

gagctcaccagctctccagcctccctttctgcgtctgtgggagaaactgtcaccatcacatgt
 E L T Q S P A S L S A S V G E T V T I T C

cgagcaagtgggaatattcacaattatntagcatgggtatcagcagaaacagggaaaatctcct
R A S G N I H N Y L A W Y Q Q K Q G K S P

CDR1


cagctcctgggtctattatacaacaaccttagcagatgggtgtgccatcaaggttcagtggcagt
 Q L L V Y Y T T T L A D G V P S R F S G S

CDR2

ggatcaggaacacaatattctctcaagatcaacagcctgcaacctgaagattttgggagttat
 G S G T Q Y S L K I N S L Q P E D F G S Y

tactgtcaacatTTTTGGGAGTACTCCTCGGACGTTCCGGTGGAGGGACCAAGCTCGAG
 Y C Q H F W S T P R T F G G G T K L E

CDR3

Figure 7:

-Ser-Lys-Lys-Phe-Ser-Arg-Ser-Asp-Pro-Asn-Phe-Ser-Gly-

Figure 8:

